Stockwinners Market Radar for May 27, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:50 EDT Ross Acquisition Corp II receives NYSE notice regarding delayed 10-Q filing - Ross Acquisition Corp II announced that it has regained compliance with Section 802.01E of the New York Stock Exchange Listed Company Manual after filing its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 with the Securities and Exchange Commission on May 27, 2021.

18:46 EDT HP Inc. CEO: Underlying trends driving performance will continue - In an interview on CNBC's Mad Money, Enrique Lores said, "We're going to continue to see hybrid work that will increase demand." Demand for PC's continues to be strong and printing has come back strong, he noted. There shouldn't be any worries about cash flow, he added. "We think the stock price is undervalued," he said.

18:26 EDT Gap CEO: We feel great about our strategy and brands - In an interview on CNBC's Mad Money, Sonia Syngal said Gap (GPS) has purpose-driven, lifestyle brands. The company saw great momentum at Old Navy and expects it to continue. It is also seeing Banana Republic take control of its position in luxury. Syngal is very excited about the company's partnership with Walmart (WMT).

18:02 EDT Dentsply Sirona increases quarterly dividend 10% to 11c per share - Dentsply Sirona approved a 10% increase in the company's quarterly dividend rate to 11c per share. The dividend is payable on July 9 to holders of record as of June 25.

17:49 EDT Franklin Street finihes properties for aggregate gross proceeds of $219.5M - Franklin Street Properties announced the completion of the sale of One Overton Park, One Ravinia Drive and Two Ravinia Drive or Franklin Street Properties a real estate investment trust announced the completion of the sale of One Overton Park, One Ravinia Drive and Two Ravinia Drive for aggregate gross proceeds of $219.5M.The Company expects to record an aggregate gain of approximately $23M in the second quarter of 2021 in connection with the sale of the Properties. George J. Carter, Chairman and Chief Executive Officer of FSP, commented as follows: "We are pleased to announce the completion of the sale of the Properties. The proceeds from this sale represent a significant portion of our previously announced 2021 disposition guidance in the range of $350 million to $450M aggregate gross proceeds. As previously announced, the proceeds are intended to be used primarily for debt reduction." "We are pleased to announce the completion of the sale of the Properties. The proceeds from this sale represent a significant portion of our previously announced 2021 disposition guidance in the range of $350 million to $450 million in aggregate gross proceeds. As previously announced, the proceeds are intended to be used primarily for debt reduction." This press release, along with other news about FSP, is available on the Internet at www.fspreit.com. We routinely post information that may be important to investors in the Investor Relations section of our website.

17:32 EDT Ballard Power receives follow-on fuel cell order for Solaris buses in Frankfurt - Ballard Power announced purchase orders from Solaris Bus & Coach, a leading European bus and trolleybus manufacturer and Ballard partner headquartered in Bolechowo, Poland, for 13 Ballard FCmove fuel cell modules to power 13 Fuel Cell Electric Buses deployed with In-der-City-Bus, which operates bus routes in Frankfurt, Germany. Ballard plans to ship the modules in 2021 and the buses are planned for deployment in 2022. Each of the single decker Solaris Urbino 12 hydrogen buses is capable of traveling 350 kilometers on a single hydrogen refueling.

17:19 EDT HollyFrontier to replace Service Properties in S&P 400 at open on 6/4

17:09 EDT Yext jumps 15% to $14.15 after Q1 results beat, FY22 revenue guidance raised

17:02 EDT Disney elects Amy Chang, Calvin McDonald to Board of Directors - The Walt Disney Company (DIS) Board of Directors announced the election of two new directors: Amy Chang, veteran technology executive, and Calvin McDonald, CEO of global athletic apparel company lululemon athletica (LULU). The elections of Chang and McDonald are effective immediately.

17:01 EDT Atlantic Avenue Acquisition receives NYSE notice regarded delayed report - Atlantic Avenue Acquisition Corp announced that, on May 25, 2021, it received a notice from NYSE Regulation stating that the company is not in compliance with the Section 802.01E of the Listed Company Manual because the company failed to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 with the Securities and Exchange Commission. The NYSE informed the company that the company has six months from the 10-Q filing due date to file the Form 10-Q. The Notice has no immediate effect on the listing or trading of the company's securities on the NYSE.

16:53 EDT Coinbase announces Coinbase Fact Check, 'in the age of misinformation' - Brian Armstrong, of Coinbase, said in part in a blog posting earlier: "As Coinbase and the cryptoeconomy grow, we've seen more interest from the media, government, and the general public in our business and in crypto overall. This increased awareness has been great. Unfortunately, we also see misinformation published frequently as well, whether in traditional media, social media, or by public figures.This doesn't always come from negative intentions. Our business, and crypto, can be difficult to understand, and often people are rushed to post first impressions online, making mistakes in the process. At other times, misinformation comes from people pushing their own agenda, or from those who have a conflict of interest. This is not unique to our business or industry of course. Every company experiences this to some degree, and it can be incredibly frustrating. So how should companies respond to misinformation? The choices Option 1: turn the other cheek; As Coinbase and the cryptoeconomy grow, we've seen more interest from the media, government, and the general public in our business and in crypto overall. This increased awareness has been great. Unfortunately, we also see misinformation published frequently as well, whether in traditional media, social media, or by public figures. This doesn't always come from negative intentions. Our business, and crypto, can be difficult to understand, and often people are rushed to post first impressions online, making mistakes in the process. At other times, misinformation comes from people pushing their own agenda, or from those who have a conflict of interest. This is not unique to our business or industry of course. Every company experiences this to some degree, and it can be incredibly frustrating. So how should companies respond to misinformation? The choices Option 1: turn the other cheek. Option 3: publish the truth I believe there is a reasonable middle ground between these first two options, which is to simply publish the truth, in a thoughtful and respectful way, and build a direct relationship with your audience....Today we're announcing a section of our blog called "Fact Check". We will use this section of the blog to combat misinformation and mischaracterizations about Coinbase or crypto being shared in the world...Crypto is a rapidly emerging space with growing attention and focus on it right now. Unfortunately, with this attention comes a lot of misinformation that is damaging, not only for companies like Coinbase, but for the space broadly. We want to do our best to ensure that when a customer, a regulator, or another important stakeholder is doing their research on crypto that they're seeing information that is accurate and objective. Reference Link

16:42 EDT Ulta Beauty up 4.5% to $343 per share after Q1 earnings beat, FY guidance raise

16:37 EDT Gores Technology Partners II receives Nasdaq notice over delayed report - Gores Technology Partners II announced that, on May 21, 2021, it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the company failed to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 with the Securities and Exchange Commission. The Notice has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Capital Market. As previously disclosed in the Form 12b-25 filed on May 18, 2021 by the company, on April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the SEC together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled "Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies." As result of the SEC Statement, the Company's management is reevaluating the accounting treatment of the redeemable warrants that were included in the units issued by the Company in its initial public offering and the redeemable warrants that were issued in a private placement, and concluded that the Warrants should be reclassified as derivative liabilities.

16:33 EDT Gores Metropoulos II receives expected notice from Nasdaq over delayed report - Gores Metropoulos II announced that, on May 21, 2021, it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the company failed to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 with the Securities and Exchange Commission. The Notice has no immediate effect on the listing or trading of the company's securities on the Nasdaq Capital Market. As previously disclosed in the Form 12b-25 filed on May 18, 2021 by the company, on April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the SEC together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled "Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies." As result of the SEC Statement, the company's management is reevaluating the accounting treatment of the redeemable warrants that were included in the units issued by the company in its initial public offering and the redeemable warrants that were issued in a private placement, and concluded that the Warrants should be reclassified as derivative liabilities.

16:33 EDT Electromed authorizes $3.0M stock repurchase program - Electromed has approved a $3.0M stock repurchase authorization, effective as of May 26. Under the authorization, the company may repurchase common stock, par value 1c per share, with an aggregate value of up to $3.0M through May 26, 2022.

16:30 EDT Lowe's raises quarterly dividend 33% to 80c per share - The board of directors for Lowe's Companies has declared a quarterly cash dividend of 80c per share, payable August 4, 2021, to shareholders of record as of July 21, 2021. Based on its confidence in the company's continued business momentum, its growth trajectory and strong cash flow generation, the board of directors approved a 33% increase in the quarterly cash dividend. Lowe's has paid a cash dividend every quarter since going public in 1961, and it has increased the dividend for more than 25 consecutive years.

16:26 EDT Dell Technologies reports Q1 net cash from operating activities $2.2B

16:22 EDT China XD Plastics receives noncompliance notification from Nasdaq - China XD Plastics announced that as expected, it received a letter from Nasdaq notifying the company that it was not in compliance with requirements of Nasdaq Listing Rule 5250 as a result of not having timely filed its quarterly report on Form 10-Q for the quarterly period ended March 31 and because the company has not yet filed its annual report on Form 10-K for the fiscal year ended December 31, 2020.

16:21 EDT SB Financial announces 750,000 share repurchase program - SB Financial Group announced that its board of directors has authorized a share repurchase program through May 31, 2022. Pursuant to the share repurchase program, the company is authorized to purchase up to an aggregate of 750,000 common shares, equal to approximately 10% of the common shares of the company. The repurchased shares will be held as treasury shares and will be available for general corporate purposes.

16:20 EDT Arcosa names Gail Peck as new CFO - Arcosa announced the appointment of Gail Peck as its CFO and Treasurer. Ms. Peck has served as the Senior Vice President, Finance and Treasurer at Arcosa since Arcosa's launch as an independent public company in November 2018.

16:18 EDT VMware reports Q1 RPO up 9% from last year at $11.0B

16:17 EDT Gap reports Q1 SSS up 28% y/y - Old Navy Global net sales were up 27% versus 2019, and the brand maintained its position as the #2 apparel brand in the U.S. Comparable sales were up 35% year-over-year and up 25% versus 2019. Gap Global net sales declined 16% versus 2019, with permanent store closures resulting in an estimated 11% sales decline, and international COVID-closures driving an estimated 4% decline on a 2-year basis. Comparable sales increased 29% year-over-year and decreased 1% versus 2019. Banana Republic Global net sales declined 29% versus 2019. Comparable sales were down 4% year-over-year and down 22% versus 2019. Athleta net sales were up 56% versus 2019. Comparable sales grew 27% year-over-year and 46% versus 2019.

16:16 EDT Autodesk Chief Legal Officer Pascal Di Fronzo retiring - Autodesk Executive Vice President of corporate affairs and Chief Legal Officer Pascal Di Fronzo is retiring. Di Fronzo will serve in his current role until December 2021. Autodesk will begin a search to fill the chief legal officer position as Di Fronzo transitions out of this role.

16:12 EDT Innovative Industrial Properties acquires Massachusetts property for $3.1M - Innovative Industrial Properties announced it closed on the acquisition of a property in North Adams, Massachusetts, comprising approximately 70,000 square feet of industrial space. The purchase price for the property was $3.1M, excluding transaction costs. Concurrent with the closing of the purchase, IIP entered into a long-term, triple-net lease at the property with Temescal Wellness of Massachusetts, LLC for use as a regulated cannabis cultivation and processing facility upon completion of redevelopment. Temescal is expected to complete additional tenant improvements for the property, for which IIP has agreed to provide reimbursement of up to $15M. Assuming full reimbursement for the tenant improvements, IIP's total investment in the property is expected to be $18.1M. "We have been following Temescal's evolution and continued success in Massachusetts for some time, and are thrilled to begin this new long-term real estate partnership with Ted Rebholz and his team," said Paul Smithers, President and Chief Executive Officer of IIP. "The Temescal team's focus and proven success in delivering consistent, high quality cannabis products to their patients and customers over the years, in combination with their well-located dispensaries accessible to a large percentage of Massachusetts residents, have positioned them very well for the future. We look forward to supporting their real estate capital needs for many years to come, including the buildout of this new facility that is expected to dramatically enhance Temescal's production capacity as demand for high quality cannabis products continues for patients and customers throughout the Commonwealth."

16:11 EDT Teekay Corp. completes Banff decommissioning agreement - Teekay Corporation announces the completion of the remaining conditions precedent relating to the previously announced Decommissioning Services Agreement with CNR International Limited, on behalf of the Banff joint venture, whereby Teekay has engaged CNRI to decommission the Company's remaining subsea infrastructure located within the CNRI-operated Banff Field. As part of the DSA, which is now in full effect, CNRI has assumed full responsibility for Teekay's remaining asset retirement obligations for the above-mentioned facilities, which should enable CNRI to complete Teekay's Phase II work in conjunction with their other decommissioning work at the Banff Field in a more efficient manner. As part of the transaction, Teekay has now been deemed to have completed all of its prior decommissioning obligations associated with the Banff Field and as a result, the Company expects to reduce its accrued asset retirement obligations by approximately $30 million in the second quarter of 2021. "This agreement is a major milestone towards achieving our strategic goal of winding down our FPSO segment," commented Kenneth Hvid, Teekay's President and CEO. "This transaction also reflects the strong collaboration with our customer and represents the conclusion of our involvement on the Banff Field after over 20 years of successful operations."

16:04 EDT D.E. Shaw reports 5.0% passive stake in Express - D.E. Shaw disclosed a 5.0% stake in Express, which represents over 3.31M shares. The filing does not allow for activism.

15:56 EDT Capcom's 'Resident Evil Village' has sold over 4M units worldwide - Capcom (CCOEY) announced that multi-platform title "Resident Evil Village," the latest entry in the "Resident Evil" series, has shipped over 4M units worldwide, including digital sales. The game, which launched worldwide on May 7, is currently available on PC, PlayStation 4 (SONY), PlayStation 5, Xbox One (MSFT), and Xbox Series X/S. Capcom noted that "Resident Evil 7: Biohazard" has shipped a cumulative 9M units as of March 31, 2021 since the game's initial release in early 2017. Reference Link

14:35 EDT eBay announces launch of regulatory portal to 'further protect consumers' - eBay has announced the "successful pilot" of its Regulatory Portal, which it said is "part of its longstanding commitment to consumer safety." eBay stated: "The online portal allows participating authorities to flag and take down a listing, outside of the existing consumer reporting facility on site. This facility is in addition to eBay's own extensive reporting system and proactive efforts to remove prohibited items and enforce its existing policies. With the U.S. Postal Inspection Service, Westminster City Council Trading Standards, Bundesnetzagentur, Health Products Regulation Group, and over 50 other authorities around the world already onboarded, the platform has entered its beta phase. eBay is inviting selected trusted authorities from around the globe to join the taskforce, as part of the essential cooperation needed between governments, authorities, and online marketplaces to ensure consumers can stay safe shopping online." Reference Link

14:32 EDT Nintendo's 'Smash Bros.,' 'Splatoon 2' join PlayVS' high school esports leagues - Esports company PlayVS announced that it is the official scholastic partner of Nintendo with the "Super Smash Bros. Ultimate" and "Splatoon 2" games joining PlayVS' high school leagues starting this Fall season. The two games are now officially recognized as high school varsity athletics. "With these two beloved games joining our roster, the competitive high school community just got bigger, better, and even more fun with Nintendo," PlayVS said. "Students from all over the country will be able to put their skills to the test in exciting league formats, team play, and more as the next season kicks off September 20th, 2021 - and we cannot wait for you to be a part of it!" Reference Link

14:14 EDT Unity Bancorp raises dividend to 9c from 8c per share - Unity Bancorp, parent company of Unity Bank, announced that its board of directors has declared a cash dividend of 9c per common share. Such dividend is payable on June 25 to shareholders of record as of June 11 and is an increase from last quarter's 8c per share level.

13:51 EDT AWS announces general availability of Amazon ECS anywhere - Amazon Web Services, AWS, an Amazon.com, announced the general availability of Amazon Elastic Container Service ECS Anywhere, a new capability for Amazon ECS that enables customers to run and manage container-based applications on-premises using the same APIs, cluster management, workload scheduling, monitoring, and deployment pipelines they use with Amazon ECS in AWS. Amazon ECS Anywhere provides a fully managed container orchestration service that allows customers to easily run, scale, and secure Docker container applications on any customer-managed infrastructure in addition to all AWS Regions, AWS Local Zones, and AWS hybrid infrastructure deployment. There are no upfront fees or commitments to use Amazon ECS Anywhere, and customers pay only for the container instances they run. To get started with Amazon ECS Anywhere, visit: https://aws.amazon.com/ecs/anywhere Containers provide a standard way for developers to package and run applications quickly and reliably while improving resource utilization and reducing cost. Today, over 100,000 customers run their containers in the cloud using Amazon ECS because of its performance at scale, reliability, security, and simplicity. However, some customers have data residency, latency, regulatory, or compliance considerations that require them to run applications on their own infrastructure. Other customers want to make use of their investment in unused on-premises compute capacity without adding to their operational overhead. Both scenarios require customers to manually install, operate, and manage on-premises container orchestration software-separate from the infrastructure they operate in the cloud. Before today, these customers have had to install and manage their own container orchestration software and use disparate tooling across their cloud and on-premises environments. This situation not only leads to operational overhead, but also slows the pace of delivering new business capabilities. What customers want instead is a single, fully managed solution that works anywhere they deploy containers.

12:00 EDT Realogy falls -8.6% - Realogy is down -8.6%, or -$1.67 to $17.76.

12:00 EDT OneConnect falls -15.8% - OneConnect is down -15.8%, or -$2.95 to $15.73.

12:00 EDT Ooma rises 16.0% - Ooma is up 16.0%, or $2.62 to $18.99.

11:51 EDT Sony's 'MLB The Show 21' debuted as best-selling game of April, says NPD - NPD analyst Mat Piscatella said that Sony's (SONY) "MLB The Show 21" debuted as both the best-selling game of April 2021 as well as the 3rd best-selling game of 2021 year to date. Launch month dollar sales of "MLB The Show 21" set a new franchise high. "MLB The Show 21" was the best-selling game of the month on PlayStation platforms, and ranked 2nd on Xbox (MSFT), though Piscatella noted that digital sales on Xbox platforms are not included in the rankings. Nintendo's (NTDOY) "New Pokemon Snap" was the 3rd best-selling game of April 2021 and was the month's best-selling game on Nintendo platforms. Launch month physical sales of "New Pokemon Snap" more than doubled those of "Pokemon Snap," which debuted in the July 1999 tracking month. Warner Bros. (T) game "Mortal Kombat 11" placed among the top 10 best-sellers of the month for the first time since ranking 9th in July 2020. "Mortal Kombat 11" is currently the 13th best-selling game of 2021 year to date. EA's (EA) "It Takes Two" climbed to 9th on the April 2021 best-sellers chart after placing 22nd in its March debut month. "It Takes Two" was the 3rd best-selling game of April on Xbox platforms while ranking 8th on PlayStation. Other top sellers for the month of April were Activision's (ATVI) "Call of Duty: Black Ops Cold War," Square Enix's (SQNXF) "Outriders" and "NieR: Replicant," Capcom's (CCOEY) "Monster Hunter: Rise," and Sony's "Returnal." Other companies in the video game space include Tencent (TCEHY), Ubisoft (UBSFY), and GameStop (GME). Reference Link

11:35 EDT 1847 Goedeker says 'unaware of reason' for stock volatility - 1847 Goedeker announced in response to unusual market activity that after "speaking with its directors, major shareholders and other relevant persons, it is unaware of the reason behind today's stock price volatility." The company confirms "there is no corporate development relating to its business and affairs that has not been previously announced," it stated in a press release.

11:03 EDT Square announces new integration with Google Merchant Center - Square (SQ) announced a new integration with Google Merchant Center (GOOGL) that it said "makes it easier for Square sellers to reach new customers through direct product listings on Google." Square for Retail merchants can now have products from their businesses populate right alongside items from other ecommerce stores of all sizes, helping smaller sellers to increase reach and revenue by uncovering new customers buying online, the company stated. "Our goal is to help sellers reach new customers. Online sales have been a significant revenue driver for sellers of all types and sizes over the past year. We're looking forward to partnering with Google to unlock even more opportunities for retailers as they look toward the future and begin to rebuild," said Alyssa Henry, Executive Vice President, Square.

10:58 EDT Realogy down 9.7% after announcing $300M exchangeable senior notes offering

10:07 EDT Nevada GCB to lift social distancing, occupancy limitation rules on casinos - The Nevada Gaming Control Board stated in a notice issued yesterday that effective 12:00 am on Tuesday, June 1, the Board rescinds all applicable COVID-19 mitigation protocols issued pursuant to section 18 of Emergency Directive 044, including, without limitation, Industry Notice #2021-41 and the Board's "Health and Safety Policy for Continued Mitigation of the Spread of COVID-19 for Nonrestricted Licensees." The notice states: "As of June 1, 2021, none of Nevada's counties will retain social distancing or occupancy limitations that would apply to a gaming licensee. If the status of the spread of COVID-19 changes in such a way that a county amends its Local Plan, the Board expects each licensee to fully comply with such changes." Publicly traded companies in the casino gaming space include Boyd Gaming (BYD), Caesars (CZR), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn National (PENN), and Wynn Resorts (WYNN).

10:01 EDT Flowers Foods raises quarterly dividend 5% to 21c from 20c per share - Payable on June 24 to shareholders of record on June 10.

10:00 EDT OneConnect falls -12.2% - OneConnect is down -12.2%, or -$2.27 to $16.41.

10:00 EDT Vista Outdoor rises 8.8% - Vista Outdoor is up 8.8%, or $3.52 to $43.48.

10:00 EDT BIT Mining Limited rises 17.1% - BIT Mining Limited is up 17.1%, or $1.21 to $8.29.

09:47 EDT Express falls -7.3% - Express is down -7.3%, or -36c to $4.60.

09:47 EDT Nam Tai Property rises 8.1% - Nam Tai Property is up 8.1%, or $1.91 to $25.50.

09:47 EDT SOS Limited rises 13.2% - SOS Limited is up 13.2%, or 43c to $3.69.

09:31 EDT CleanSpark executes partnership with FlowGen - CleanSpark and FlowGen announced they have entered into a collaborative memorandum of understanding . Under the terms of the MOU, FlowGen has agreed to use CleanSpark's mPulse controls solution in all of its microgrid projects worldwide. In addition, CleanSpark was granted the exclusive distribution rights for FlowGen's advanced wind turbine solutions throughout North and South America.

09:23 EDT Genius Brands announces content acquisitions for Kartoon Channel! - Genius Brands International continues to grow its content offering with the acquisition of series from third party producers. Since launching in June 2020, Kartoon Channel!, which is now widely available and fully distributed in the U.S. across all platforms, has significantly expanded its catalog of original and third-party programming. On April 23, 2021, Genius Brands launched its first Kartoon Channel! original, Stan Lee's Superhero Kindergarten, which has since garnered over 22 million views. The new content acquisitions for Kartoon Channel! include classic evergreen and new popular series and feature films. From WildBrain, Genius Brands has licensed the rights to Super Mario Bros.; Adventures of Paddington Bear. Trollz; Madeline; and Liberty's Kids. From Nelvana, movies and series acquired for Kartoon Channel! include Donkey Kong Country; Movie specials from the Franklin franchise, including Franklin and the Green Knight, Franklin and the Turtle Lake Treasure, A Franklin and Friends Adventure: Polar Explorer, A Franklin and Friends Adventure: Deep Sea Voyage, Franklin Back to School, and Franklin's Magic Christmas; and lastly, The Santa Clause Brothers movie special ABC Australia has licensed to the Kartoon Channel! the rights to The Wiggles World; Wiggle Pop special, among others.

09:21 EDT Hyster announces new high-capacity forklift models - Hyster Company announces new high-capacity forklift models with factory integrated lithium-ion power, known as the J230-360XD and J360XD36-48 in the Americas, and the J10-18XD in Europe, Middle East, and Africa and Asia-Pacific. All models feature 350-volt lithium-ion battery power that delivers performance comparable to traditional diesel power in 23,000- to 36,000-pound load capacities, helping heavy-duty applications achieve emissions goals without compromising performance.

09:15 EDT Burlington Stores: Comp sales trends started to 'cool off' in April - Says stimulus checks added 10-15 percentage points of comp store sales growth in Q1.

09:11 EDT Aptevoin expansion phase of anti-leukemia drug APVO436 in adult patients - Aptevo Therapeutics announced that the company has initiated the expansion phase of lead anti-leukemia drug candidate, APVO436, in adult patients with acute myeloid leukemia, AML, with a multi-center, multi-arm trial using the active recommended dose identified in the dose escalation phase of the study. During Part 1, APVO436 exhibited a manageable side effect profile, encouraging single agent activity and a promising benefit to risk profile in relapsed AML patients. The Company has plans to submit data from the dose escalation phase for publication later this year.

09:06 EDT Roku inks' first ever' pay-one window rights deal With Saban Films - Roku and Saban Films announced a landmark agreement granting Roku the pay-one window streaming rights to movies released by Saban Films. Under the agreement, a selection of Saban's 2021 film slate will stream free exclusively on Roku's ad-supported streaming service, The Roku Channel, in the United States and Canada following theatrical and home entertainment release. The deal is the first ever pay-one licensing agreement for Roku. Saban Films President Bill Bromiley commented, "Streaming has become an incredible way to experience movie-making magic from the comfort of your own home and we are thrilled to bring an extraordinary lineup of entertainment to The Roku Channel and America's No. 1 TV streaming platform."* Saban's first film to premiere on The Roku Channel will be "Echo Boomers" starring two-time Academy Award nominee Michael Shannon and Patrick Schwarzenegger on June 15. Future film debuts include "Happily" starring Joel McHale and Kerry Bishe; "Percy VS Goliath" starring Academy Award winner Christopher Walken, Christina Ricci and Zach Braff; "Under the Stadium Lights" starring Laurence Fishburne and Milo Gibson, and more to be announced at a later date. "Saban Films is a great partner with a history of creating standout films," said Rob Holmes, VP of Programming for Roku. "This first-of-its-kind agreement allows us to bring these compelling films exclusively to our large, engaged audience for free, and to build upon the incredible growth of The Roku Channel."

09:05 EDT Boeing to pay at least $17M to settle FAA enforcement cases on 737 - The Boeing Company will pay at least $17M in penalties and undertake multiple corrective actions with its production under a settlement agreement with the Federal Aviation Administration. The FAA found that the Chicago-based manufacturer installed equipment on 759 Boeing 737 MAX and NG aircraft containing sensors that were not approved for that equipment; submitted approximately 178 Boeing 737 MAX aircraft for airworthiness certification when the aircraft potentially had nonconforming slat tracks installed; and improperly marked those slat tracks. Boeing will pay the $17M penalty within 30 days after signing the agreement. If Boeing does not complete certain corrective actions within specific timeframes, the FAA will levy up to $10.1M in additional penalties. The FAA will continue its oversight of Boeing's engineering and production activities and is actively implementing oversight provisions from the 2020 Aircraft Certification, Safety, and Accountability Act. Reference Link

09:05 EDT IMAC announces results from internal analysis of treatment outcomes - IMAC Holdings announced results from an extensive internal analysis of treatment outcomes for musculoskeletal conditions performed at IMAC Regeneration Centers, which showed approximately 81% of IMAC patients reported improvement in movement, which is consistent with the data measured over the past three years. IMAC analyzed functional disabilities primarily affecting the knees, lower back, neck, shoulders, hips, legs and ankles. Data was collected from patients during initial examinations, re-examinations and at discharge intervals during patients' course of care. IMAC examined patient functional improvement following treatment at IMAC Regeneration Centers between 2017 and the first quarter of 2021 utilizing standardized disability indexes. A total of 875 patients with an average age of 72 years and receiving 80.7 days of treatment were evaluated with each patient receiving non-opioid medical treatments in combination with physical therapy. More than 81%, or 712, exhibited up to 79% improvement in functionality. For the study, 152 patients showed less than 1% change in functional ability, and only 11 patients regressed. In IMAC's analysis, the percentage of patients reporting improvement for each disability category was as follows: 81% of those treated for knee conditions, 80% of those treated for lower back conditions, 90% of those treated for neck conditions, 73% of those treated for shoulder conditions, 78% treated for hip conditions, 86% treated for leg conditions and 80% of those with ankle conditions. The average treatment duration was 80.87 days, and the average patient age was 72.2 years.

09:03 EDT Quipt Home Medical to begin trading on Nasdaq - Quipt Home Medical is pleased to announce the start of trading on The Nasdaq Capital Market under the trading ticker symbol "QIPT" at the market open today. The Company's common shares will continue to be listed on the TSX Venture Exchange under the symbol "QIPT".

08:58 EDT Burlington Stores sees FY20 total sales growth of 20% for FY, consensus $8.14B

08:57 EDT Burlington Stores sees 'flattish' comp sales for 2H

08:53 EDT Hyliion Holdings announces initial results from truck loan program - Hyliion Holdings announced initial results from a truck loan program launched in conjunction with Portland-based natural gas provider, NW Natural, which featured Hyliion's Hybrid CNG solution. As part of the program, Hyliion collaborated with NW Natural to equip a Freightliner Cascadia day cab with their Hybrid compressed natural gas solution, a self-charging powertrain that boosts performance by adding up to 120 horsepower to a Class 8 semi-truck-enough power to allow the vehicle to perform more like a diesel truck. The Hybrid CNG truck was loaned to three Oregon-area fleet operators-Baker Rock Resources, Tillamook County Creamery Association, and Calportland-over a three-week trial period. Each participant reported that the Hyliion Hybrid solution delivered more power, greater sustainability, and improved operating costs.

08:47 EDT Omniq receives purchase order to deploy PERCS Cloud-hosted Software - omniQ Corp announced the receipt of a Software as a Service recurring revenue agreement from ASPIS Parking to deploy its PERCS Cloud-hosted Software for Georgia State University. The agreement also includes deployment of multiple omniQ's eCite Pro enforcement vehicles, which includes omniQ's complete AI mobile Vehicle Recognition System, for enforcement of permit violations and citation issuance.

08:43 EDT Quanta's Medolife Rx produces medical batch of escozine - Medolife Rx, which is a majority owned subsidiary of Quanta, announced that it successfully produced a pharmaceutical-quality batch of its lead drug candidate escozine through its production footprint in the Dominican Republic, or DR. The company is ready to submit the batch to the Ministry of Health, its next step in seeking approval for further clinical trials in the country. Through an exclusive relationship with the government of the DR, Medolife owns a scorpion reservation and research facility, as well as an extraction facility nearby where it is able to humanely extract the peptides used in escozine. After further building out and onboarding of essential staff, the company has successfully produced a full batch of escozine. This batch specifically ran for submission to the Ministry of Health in the DR. This is the next step in achieving approval from the regulatory body to continue clinical trials on escozineas a treatment for the SARS-CoV-2 virus. Once the batch is reviewed and the Medical Bioethics committee issues approval of the study's construct, Medolife plans to conduct a Phase III double-blind placebo clinical trial, seeking regulatory approval of the drug. Beyond its COVID-19 clinical program on Escozine, the product was also recently awarded product re-registration as an alternative medicine for the treatment of cancer. The company has conducted clinical studies on escozine as a therapeutic for both COVID-19 and multiple forms of cancer, including ovarian and bladder cancer. The company is currently awaiting a response on its pre-IND filing with the Food and Drug Administration, which it expects in mid-June 2021.

08:40 EDT Abercrombie & Fitch, The Trevor Project launch co-designed pride collection - Abercrombie & Fitch, a division of Abercrombie & Fitch, announces the launch of its 2021 Pride collection for both the Abercrombie & Fitch and abercrombie kids brands. The collection was co-created with The Trevor Project, the world's largest suicide prevention and crisis intervention organization for lesbian, gay, bisexual, transgender, queer and questioning young people. "Over the last nine months, Abercrombie & Fitch worked hand-in-hand with The Trevor Project to identify the prints, colors, fabrics, fits and technical details to bring this unique and celebratory collection to life. The 24-piece gender-inclusive adults collection, available in sizes XXS-XXXL, features t-shirts, shorts, hoodies, jackets, sandals, hats, socks and more, as well as an exclusive rainbow-clad pride edition of A&F's iconic fragrance, Fierce. The 11-piece gender-inclusive kids Pride collection is part of abercrombie kids' "everybody collection" and adds to the brand's Abercrombie Family initiative with unique mini-me styles so the whole family can celebrate together. The kids collection features t-shirts, hoodies, bucket hats, scrunchies, sunglasses and more," the company said. This year's Pride collection is available in stores for Pride Month and online throughout the year at abercrombie.com and abercrombiekids.com. In addition to the year-long roundup campaign, Abercrombie & Fitch will be making an initial $200,000 donation to The Trevor Project. Since the partnership began in 2010, Abercrombie & Fitch and its customers have donated more than $2M to The Trevor Project.

08:39 EDT Best Buy: Revenue growth for first three weeks of Q2 up 30% - Comments taken from Q1 earnings conference call.

08:38 EDT FuelCell Enbridge appoints Cynthia Hansen to board of directors - FuelCell Energy (FCEL) announced that its board of directors has appointed Cynthia Hansen to serve as a new independent director, effective May 25. Hansen is currently Executive Vice President and President, Gas Distribution and Storage at Enbridge (ENB). Cynthia serves on the boards of Energir the Ontario Energy Association and the Canadian Gas Association. Hansen's appointment expands the Board to six directors, five of whom are independent. She will be a member of the board's Executive, Nominating and Corporate Governance, Audit and Finance, and Compensation Committees.

08:35 EDT Eloxx Pharmaceuticals receives award of $2.6M from Cystic Fibrosis Foundation - Eloxx Pharmaceuticals announced that the company has received an award of up to $2.6M from the Cystic Fibrosis Foundation. This award will help to identify optimized oral RMAs for further development in the treatment of cystic fibrosis patients with nonsense mutations. "We are honored to receive this funding from the Cystic Fibrosis Foundation in our ongoing commitment to identify and develop new treatments for CF. Their support of novel technologies enables critical research to advance and further evaluate the potential of the TURBO-ZM synthetic chemistry platform to develop a new class of therapies. We have tremendous confidence in the potential of RMAs designed with TURBO-ZM to treat rare genetic diseases," said Sumit Aggarwal, President and CEO. "In preclinical models, novel RMAs have demonstrated the potential for significant readthrough and functional activity."

08:34 EDT Inotiv announces purchase of St. Louis facility for $4.7M - Inotiv announced that the Company has completed the purchase of its previously leased St. Louis facility for approximately $4.7M. In early June 2021, the Company intends to commence construction on approximately 20,000 square feet of unfinished shell space at the 50,000 square foot facility, expanding the Company's capacity to serve its client base with more comprehensive and integrated service offerings. The expansion will include laboratories for increased drug metabolism & pharmacokinetics technology and capability, as well as a new cell and molecular biology suite capable of delivering in vitro solutions in pharmacology and toxicology. The Company will fund the purchase of the facility and expansion costs by proceeds from the public offering that the Company completed in April 2021, and a new $4.8M term loan from First Internet Bank.

08:33 EDT Saratoga Investment board increases quarterly dividend 1c to 44c per share - Saratoga Investment announced that its board of directors has declared a quarterly dividend of 44c per share for the fiscal quarter ended May 31, payable on June 29, to all stockholders of record at the close of business on June 15. This is an increase of 1c per share from last quarter. This is the second dividend declared in fiscal year 2022.

08:30 EDT Texas Capital Bank appoints Don Goin as CIO - Texas Capital Bank, and its parent company Texas Capital Bancshares, announced the following leadership appointments: Joe Valenzuela as Senior Manager, Diversity, Equity, & Inclusion, effective May 19, 2021; Don Goin as Chief Information Officer, effective May 27, 2021; and Madison Simm as President of Mortgage Finance, following the retirement of Jack Nunnery, effective August 2, 2021. . As Vice President, Senior Manager, DEI, Mr. Valenzuela will work closely with the leadership team and the Company's DEI Council, and he will engage the Company's employees to accelerate its efforts to build a culture that embraces diverse voices and perspectives, and attracts world-class diverse talent. The Company's goal is to drive meaningful change for the good of society, its clients, and the organization. As Chief Information Officer, Mr. Goin will oversee the Company's sizeable technology organization, its long-term technological strategies, and the innovative solutions it provides its clients. He will oversee the Company's use of technology to execute its business strategy, drive agility, improve efficiency, and build an exceptional client digital experience. Simm, currently Mortgage Finance Executive Vice President at Texas Capital Bank, will succeed Mr. Nunnery as President of Mortgage Finance upon retirement. In this role, Mr. Simm will be responsible for overseeing all business solutions delivered through the bank's Mortgage industry vertical, including Warehouse Lending, Mortgage Specialty Lending, and Treasury and Liquidity. Valenzuela served as Executive Director of Diversity & Inclusion at Superior Review from October 2009 to October 2020. Goin has served as CIO and Director of T&O at Santander Consumer, Digital Operations Officer at Capital One Financial Services, and CIO at Capital One Auto Financing.

08:29 EDT Medtronic 'comfortable' with Street consensus on Q1 revenue - Consensus is $7.84B.

08:27 EDT Outlook Therapeutics expects to initiate additional NORSE trials in late 2021 - The virtual Clinical Day concluded with an overview of the pre-commercialization initiatives that are underway in anticipation of a potential FDA approval in 2022. CCO Jeff Evanson detailed how Outlook Therapeutics is working to position ONS-5010, if approved, to address both unmet clinical and market needs. If approved, ONS-5010 is not only expected to provide retina patients with the safety and efficacy of an FDA-approved bevacizumab, but Outlook Therapeutics intends to work collaboratively with payors and the retina community to offer it at a responsible price that meets their needs while still delivering value to Outlook Therapeutics' shareholders. Mr. Evanson also discussed the potential value to clinicians and patients of providing ONS-5010 in a pre-filled ophthalmic syringe. "Assuming we receive FDA approval for ONS-5010 in 2022, we plan at that time to file a supplementary application for approval to provide the product in a pre-filled ophthalmic syringe; we would expect syringe approval within four to six months of that application submission. Based on our market research, we believe the retina community will welcome a pre-filled, silicone-free syringe that meets the strict specifications for ophthalmic use," said Mr. Evanson. Outlook Therapeutics has early launch planning well underway, including distribution, sales force planning, physician and patient outreach, key opinion leader support and payor community engagement. Outlook Therapeutics is also developing registration documents on a parallel path for approvals in Europe and expects to submit them shortly after completing the filing to the FDA. Mr. Evanson emphasized that while Outlook Therapeutics remains in discussion with potential strategic commercialization partners, particularly for European markets, Outlook Therapeutics is preparing to launch ONS-5010 in the United States by itself, pending FDA approval. The ONS-5010 BLA will be submitted to the FDA under the PHSA 351(a) regulatory pathway for new biologics, and if approved will have 12 years of exclusivity in the $13.1 billion global market for anti-VEGF retina therapies. In addition to pursuing approval for wet AMD, Outlook Therapeutics holds FDA SPA Agreement Letters from the FDA to conduct pivotal registration clinical trials for DME and BRVO. Outlook Therapeutics expects to initiate NORSE FOUR for BRVO and NORSE FIVE and NORSE SIX for DME in late 2021.

08:22 EDT Outlook Therapeutics provides recap of virtual Clinical Day - Outlook Therapeutics hosted a virtual Clinical Day on May 20, 2021 to provide an update on the clinical progress of ONS-5010 for treatment of wet age-related macular degeneration. If approved, ONS-5010 will be the first and only ophthalmic formulation of bevacizumab approved to treat retinal conditions. The Outlook Therapeutics management team - Lawrence Kenyon, President, CEO and CFO, Terry Dagnon, COO, and Jeff Evanson, CCO - was joined by leading retina specialists Mark Humayun, MD, PhD, Medical Advisor to Outlook Therapeutics, and Firas Rahhal, MD, Senior partner at Retina-Vitreous Associates Medical Group and Associate Clinical Professor of Ophthalmology at the UCLA School of Medicine. "As we near the end of the ONS-5010 registration program, we are excited to share the continued clinical progress that will culminate with the topline readout of pivotal data in just a few months," said Mr. Kenyon. "Together with Drs. Humayun and Rahhal, both of whom are practicing retina surgeons and well-known authorities in the retinal community, we are confident that ONS-5010, if approved, will offer a valuable new treatment option to clinicians and their retina patients and address many of the shortcomings that currently exist in the treatment landscape for wet AMD."

08:17 EDT Victoria Gold announces normal course issuer bid - Victoria Gold announces its intention to complete a normal course issuer bid. The Company has received approval from the Toronto Stock Exchange to purchase for cancellation, from time to time over a 12-month period, common shares of the Company listed on the TSX in an aggregate amount of up to 3,122,493 Common Shares. Purchases for cancellation under the NCIB Program may commence on June 1, 2021 and will terminate on May 31, 2022 or on such earlier date as the NCIB Program is complete. Purchases of Common Shares under the NCIB Program will be made through the facilities of the TSX and other alternative Canadian trading systems, in accordance with the rules of the TSX. On the date of approval, the average daily trading volume of the Common Shares for the previous six calendar months was 266,191 Common Shares. Subject to the TSX's block purchase exception, on any trading day, purchases under the NCIB Program will not exceed 66,547 Common Shares. The price that the Company will pay for any Common Shares purchased under the NCIB Program will be the prevailing market price at the time of purchase. Any Common Shares purchased by the Company will be cancelled. As of May 25, 2021, there were 62,449,874 Common Shares issued and outstanding. The 3,122,493 Common Shares that may be repurchased under the NCIB Program represents 5% of the Common Shares issued and outstanding. The actual number of Common Shares repurchased under the NCIB Program and the timing of such repurchases will be at Victoria's discretion and shall be subject to the limitations set out in the TSX Company Manual. The board of directors of Victoria believes that the underlying value of the Company may not be reflected in the market price of the Common Shares from time to time and that, accordingly, the purchase of Common Shares will increase the proportionate interest in the Company of, and be advantageous to, all remaining shareholders of the Company. To the knowledge of the Company, no director, senior officer or other insider of the Company currently intends to sell any Common Shares under the NCIB Program. However, sales by such persons through the facilities of the TSX may occur if the personal circumstances of any such person change or any such person makes a decision unrelated to these purchases under the NCIB Program. If during the course of the NCIB Program, the Company becomes aware that such persons intend to sell their Common Shares then the Company will not intentionally acquire such Common Shares pursuant to the NCIB Program. The benefits to any such person whose shares are purchased would be the same as the benefits available to all other holders whose shares are purchased. Victoria has appointed BMO Nesbitt Burns Inc. to make any purchases under the NCIB Program on its behalf.

08:15 EDT OFS Credit increases common stock distribution to 54c - OFS Credit announced that its Board of Directors has declared a 54c per share quarterly distribution, an approximate 2% increase from the prior quarter, for common stockholders for the quarter ending July 31. The distribution for common stockholders will be paid in cash or shares of our common stock at the election of stockholders. The total amount of cash distributed to all stockholders will be limited to 20% of the total distribution to be paid, excluding any cash paid for fractional shares. "The remainder of the distribution will be paid in the form of shares of our common stock. The exact distribution of cash and stock to any given stockholder will be dependent upon his/her election as well as elections of other stockholders, subject to the pro-rata limitation. Management believes that the cash and stock distribution will allow the Company to strengthen its balance sheet and to be in position to capitalize on potential future investment opportunities. Management believes its commitment to strong, long-term performance is aligned with the interests of OFS Capital Management, our investment advisor who, together with other insiders, own approximately 10% of the Company's common stock," the company said in a statement.

08:10 EDT HighCape Capital reminds stockholders to vote for business combination - HighCape Capital Acquisition reminds its stockholders of record as of the close of business on May 10, 2021 to vote at the upcoming special meeting of stockholders held virtually at https://www.cstproxy.com/highcape/sm2021 on June 9, 2021 at 10:00 a.m. Eastern Time to approve the proposed business combination with Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics. The business combination cannot be completed unless the proposal to approve the business combination receives the affirmative vote of a majority of the votes cast by HighCape stockholders present in person or represented by proxy at the Special Meeting and entitled to vote, the proposal to approve the amended and restated certificate of incorporation of HighCape is approved by the affirmative vote of holders of at least a majority of the outstanding shares of HighCape Class B common stock and a majority of the outstanding shares of HighCape common stock entitled to vote, voting as a single class, and the other required transaction proposals achieve the necessary vote. Every stockholder's vote is important, regardless of the number of shares held. HighCape requests each stockholder of record as of the close of business on May 10, 2021 who has not yet voted to complete, sign, date and return a proxy card to ensure that the stockholder's vote will be represented at the Special Meeting. To ensure that one's vote is received in time to be counted at the upcoming Special Meeting, please vote today by internet or phone following the instructions on the proxy card or voting instruction form.

08:09 EDT Leidos' QTC awarded FBI medical exams contract worth up to $110M - QTC Medical Services, a Leidos company, was recently awarded a new prime contract to provide fitness for duty medical exam services for Federal Bureau of Investigation employees and career applicants. The indefinite delivery, indefinite quantity contract was awarded by the FBI's Human Resources Division, Medical Operations and Readiness Unit. The single-award, firm fixed price contract has a maximum value of $110M if all options are exercised. It includes a 12-month base period of performance with four 12-month options.

08:09 EDT InspireMD announces warrant exchange listing transfer to Nasdaq - InspireMD announced the Company's warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market. Trading is expected to begin on June 8, 2021, under the symbols NSPRW and NSPRZ on the Nasdaq.

08:08 EDT Neximmune announces formation of Scientific Advisory Board - NexImmune announced the formation of its Scientific Advisory Board. The SAB is comprised of distinguished academic leaders in the fields of immuno-oncology, immunology and T cell biology and their expertise spans the disciplines of basic research, translational science and clinical drug development. NexImmune's SAB members include: Jeff Weber, MD, PhD, Chair; Kevan Herold, MD, C.N.H.; Michelle Krogsgaard, PhD; Yi Lin, MD, PhD; Andreas Mackensen, MD; Marcela Maus, MD, PhD; Miguel Perales, MD; Anil Rustgi, MD; Jonathan Schneck, MD, PhD; David diCapua Siegel, MD, PhD; and Juan Varela, MD, PhD.

08:07 EDT Medipharm Labs launches CBD wellness oils in Quebec - MediPharm Labs announced it launched its first wellness products in Quebec and shipped its first order of premium CBD oils for retail sale to the Societe quebecoise du cannabis, the province's sole legal retailer for cannabis based products. MediPharm shipped its first order of its own MediPharm branded CBD oils - CBD 25 Regular Formula and CBD 50 Plus Formula - that will be for sale through the Societe quebecoise du cannabis' (SQDC) retail outlets and e-commerce platform. In Canada, in addition to Quebec, MediPharm Labs' cannabis products are available in Ontario, Nova Scotia, Alberta, British Columbia, Manitoba and Saskatchewan, with additional provinces expected to be added in 2021.

08:06 EDT United Community Banks, Aquesta Financial enter $131M merger agreement - United Community Banks and Aquesta Financial Holdings announced a definitive agreement for United to acquire Aquesta, including its wholly-owned subsidiary, Aquesta Bank. Aquesta is headquartered in Cornelius, North Carolina, a northern and fast-growing suburb of Charlotte, North Carolina situated on Lake Norman. It has a premier franchise with an experienced management team led by President and Chief Executive Officer Jim Engel, who founded Aquesta Bank in 2006. The bank's high-touch customer service is delivered to retail and business customers through a network of nine branches located in Charlotte's most attractive markets and also in the coastal city of Wilmington, North Carolina. Aquesta also has successful loan production offices in Raleigh, North Carolina, as well as Greenville and Charleston, South Carolina. As of March 31, 2021, Aquesta reported total assets of $752 million, with total loans of $576 million. Additionally, $586 million, or 92%, of its deposit base consists of non-CD core deposits. The transaction value is estimated at approximately $131 million, including approximately $12 million in value for outstanding options and warrants to acquire Aquesta common stock. The transaction structure includes an election for Aquesta stockholders to receive their consideration in cash, subject to a limitation that no more than 30% of the total consideration paid by United will be in cash. The stock portion of the merger consideration is based upon 0.6386 shares of United common stock being issued in exchange for each share of Aquesta common stock. The acquisition is expected to be accretive to United's earnings per share by approximately $0.06 to $0.09 in 2022, depending upon the mix of United shares and cash elected by Aquesta stockholders and is consistent with United's stated acquisition criteria pertaining to tangible book value and targeted internal rates of return. The transaction is expected to be completed in the fourth quarter of 2021 and is subject to customary conditions, including regulatory approval as well as the approval of Aquesta's stockholders.

08:05 EDT Medtronic plans to increase R&D spend by more than 10% in FY22 - Comments taken from Q4 earnings conference call.

08:04 EDT Acutus Medical receives FDA approval to initiate Atrial Fibrillation IDE Trial - Acutus Medical announced FDA approval for the company to initiate its Atrial Fibrillation Investigational Device Exemption clinical trial for the AcQBlate Force Sensing Ablation Catheter and System. This trial is expected to enroll 350 subjects in leading centers globally and will evaluate the safety and efficacy of the system in the treatment of both paroxysmal and persistent atrial fibrillation. Designed specifically to provide consistent, effective therapeutic solutions during cardiac ablation procedures, the AcQBlate Force gold-tipped catheter and system shows physicians, in real-time, how much contact force is being applied to the heart during ablations. Studies have shown the utility of real-time contact force information in helping physicians guide safe and effective therapy, which may improve patient outcomes. The AcQBlate Force Catheter and System can operate both in a stand-alone manner or in conjunction with compatible 3D mapping systems. The new ablation system is comprised of Acutus' AcQBlate Force Catheter and Qubic Force module and seamlessly integrates with the Qubic RF generator and Qiona irrigation pump. This system received a key CE Mark in late 2020 and is now commercially available in Europe. In addition to ongoing US IDE and European commercial activities, the AcQBlate Force Catheter and System is planned to serve as the work-horse delivery platform for the company's Pulsed Field Ablation program. Enrollment for the AcQBlate Force AF trial is expected to begin in the second half of 2021, once participating sites gain necessary institutional review board approvals.

07:53 EDT Bit Digital extending gains after appointment of Brock Pierce to advisory board - Shares of Bit Digital are up another 14% in the pre-market following yesterday's 9.8% rally. Yesterday afternoon, the company announced the appointment of Brock Pierce, Chairman of the Bitcoin Foundation, to its advisory board and leadership team. Piece "has been involved in Bitcoin mining since its genesis days, acquiring a significant portion of the first batch of Avalons and ran KNC's China operation, one of the world's first large scale mining operations", the company states.

07:46 EDT Moderna highlights advances and innovative vaccine research at Science Day - Moderna announced new research being highlighted as part of the Company's fourth annual Science Day. Moderna's Science Day is designed to provide insight into the continued diverse efforts underway at Moderna to better understand how to use mRNA as medicines and vaccines and underscores the Company's continued commitment to basic science and innovation. Science Day gives us an opportunity to provide insights into the advancements in our platform science and our further understanding of how to use mRNA as both a vaccine and a medicine. Our investments in basic science continue to result in major steps forward in our platform's capabilities, and these have allowed us to open new therapeutic areas and new scientific directions," said Stephen Hoge, M.D., President of Moderna. "Our investments in platform research along with our digital backbone and manufacturing plants have enabled us to create first-in-class mRNA medicines and vaccines. Today, we're excited to highlight our work to identify and address SARS-CoV-2 variants of concern, optimize our proprietary lipid nanoparticle LNP technology, and deliver mRNA to hematopoietic stem cells."

07:45 EDT Moderna highlights advances and innovative vaccine research at Science Day - Moderna announced new research being highlighted as part of the Company's fourth annual Science Day. Moderna's Science Day is designed to provide insight into the continued diverse efforts underway at Moderna to better understand how to use mRNA as medicines and vaccines and underscores the Company's continued commitment to basic science and innovation. Science Day gives us an opportunity to provide insights into the advancements in our platform science and our further understanding of how to use mRNA as both a vaccine and a medicine. Our investments in basic science continue to result in major steps forward in our platform's capabilities, and these have allowed us to open new therapeutic areas and new scientific directions," said Stephen Hoge, M.D., President of Moderna. "Our investments in platform research along with our digital backbone and manufacturing plants have enabled us to create first-in-class mRNA medicines and vaccines. Today, we're excited to highlight our work to identify and address SARS-CoV-2 variants of concern, optimize our proprietary lipid nanoparticle LNP technology, and deliver mRNA to hematopoietic stem cells."

07:44 EDT Anaplan sinks 12% to $50 after Q1 results, departure of CFO

07:36 EDT Anaplan CFO David Morton, Jr. will step down - Anaplan also announced that Chief Financial Officer David H. Morton, Jr. will step down from his position later this year to spend more time with his family. Anaplan has initiated a search for its next CFO with the assistance of an external search firm, and Dave will continue in his role until his successor is hired. "On behalf of the Board and the leadership team, I thank Dave for his years of service to Anaplan and his many contributions to advance our finance organization. We wish him the best as we initiate the process to find Anaplan's next CFO," said Frank Calderoni, President and CEO of Anaplan. "It has been a privilege to work alongside so many talented people at Anaplan, and now is the right time to begin this transition," said Morton. "The need for scenario-based planning has never been greater and Anaplan is fully focused on executing against the opportunities ahead. I look forward to doing whatever I can to support Anaplan's path forward, including assisting with the search process."

07:35 EDT Field Trip Health receives conditional approval to uplist to TSX - Field Trip Health is pleased to announce that it has received conditional approval to list its common shares and warrants on the Toronto Stock Exchange. The listing is subject to the company fulfilling certain requirements of the TSX in accordance with the terms of its conditional approval letter dated May 26, 2021. Field Trip is actively working to satisfy the requirements and conditions that were highlighted in the approval letter and management is confident that all conditions for listing will be met in the coming weeks. Upon obtaining final approval, the Company will issue an additional press release to inform shareholders when it anticipates that its common shares will commence trading on the TSX. Upon completion of the final listing requirements, the Company's common shares will be delisted from the CSE and commence trading on the TSX under the trading symbol "FTRP" and the warrants will trade under the symbol "FTRP-WT". The Company's shares will continue to trade on the OTCQX market under the symbol "FTRPF."

07:34 EDT Osino Resources reports drill results from Twin Hills Gold Project - Osino Resources is pleased to provide an update on drill results from its ongoing infill and expansion drill program at Osino's flagship Twin Hills Gold Project in the Erongo Region of Namibia. Results include a wide, high-grade intercept at Clouds East from a deeper hole below the pit shell. More than half of this intersected high-grade zone is outside of the current resource envelope, suggesting possible future incremental resource growth. The maiden resource was released on April 12th, 2021 including 0.43Moz @ 1.00g/t in the Indicated category and 1.47Moz at 1.08g/t in the Inferred category at a cut-off grade of 0.5g/t. The infill drill program is aimed at converting the bulk of the mineralization to the Indicated and Measured Categories and includes approximately 42,000m of drilling to be completed by July 2021. Further drilling is planned for the 2nd half of the year with the aim of delineating down-dip and strike extensions to the currently defined resource outline. A total of 37,107m of infill drilling has been completed since the program started in March 2021. This includes 14,620m of diamond core from 61 holes and 22,487m of reverse circulation from 163 holes. The program is being carried out on a staggered 50m x 50m pattern resulting in an effective maximum drill spacing of approximately 32m to 35m. This will result in conversion of a significant portion of the current Inferred resource to Indicated and Measured categories. There are currently 4 Reverse Circulation rigs drilling the holes of up to 220m in depth around the margins of the modelled pit at THC, Bulge and Clouds and 5 Diamond rigs drilling the infill and step-out holes of greater than 220m depth. The remaining infill drill meters will be completed by July 2021. The current assay turn-around time is approximately 2 months, therefore the last batches from the infill drill program are expected to be reported in September 2021. Assays received after the previous press release include an intercept at Clouds East from a deeper hole to the north and below the US$1700/oz pit shell. More than half of this intersected high-grade zone is outside of the current resource envelope, indicating possible future resource growth potential. It is now clear that the Clouds East high-grade shoot continues to depths beyond 250m although the assays of some of the deeper step-out holes, outside of the resource envelope, are still outstanding. Additional step-out holes are currently being planned around OKD142 to test the down dip and strike extensions of the mineralization. Other infill assays received in the Clouds area, including OKR282, confirm consistency and width of mineralization from surface to about 150m in depth, contained within the US$1700/oz pit shell. OKR275 is on the western margin of the Clouds deposit and indicates shallow high-grade mineralization in that area. Additional infill assays at Bulge and THC continue to produce consistent, wide mineralized intercepts. Infill holes OKR184, OKR220 and OKR273 all produced wide zones of mineralization as expected and confirm mineralization from surface just below the calcrete cover. Deeper infill holes at Bulge and THC are being drilled with diamond rigs to test down dip and deeper strike extensions of the orebody as expected from 3-D modelling and structural interpretation. The gap between Bulge and THC is steadily becoming smaller with more infill drilling and the latest results in the area include OKR274 with 60m @ 0.97g/t, including 9m @ 1.82g/t and 4m @ 2.14g/t. The gap is now down to less than 200m in strike length. A total of 18,549m of drilling has been completed to date on the brownfields targets. These targets are all within a 10km radius of the THC orebody and have not been tested previously. These assays have started to arrive and will all be reported in due course.

07:32 EDT PDS Biotechnology establishes partnership with Head and Neck Cancer Alliance - PDS Biotechnology and the Head and Neck Cancer Alliance announced a partnership. This collaboration seeks to raise awareness of new and developing treatment options, including available clinical trials, for patients with HPV-attributed head and neck cancer diagnoses. Partnerships such as the one between PDS Biotech and HNCA are becoming more common in the patient advocacy and biotechnology spaces. By combining their efforts, partners can more efficiently spread the word about emerging treatments, clinical trials, and additional options for patients who may not have responded to traditional therapies. "Raising awareness of treatment options for patients and their families who are dealing with head and neck cancer that has returned or spread is critical," said Dr. Lauren Wood, Chief Medical Officer of PDS Biotech. "Treatment options for these patients can be limited and the search often expands to include investigational therapies being studied in clinical research. We're excited to partner with the HNCA to raise awareness of these options for patients and physicians."

07:17 EDT Neptune Wellness' cannabis brand PanHash now available in Quebec - Neptune Wellness launched PanHash in Quebec. PanHash, Neptune's cannabis brand, is launching two products with a high concentration of CBD: a cannabis oil and capsules. Neptune cannabis products are available for adult-use in Alberta, British Columbia and Ontario.

07:15 EDT Skylight Health announces date of Nasdaq Exchange listing - Skylight Health Group is pleased to announce that further to its press release dated May 13, 2021, it has received confirmation from The Nasdaq Stock Market that its common shares will be able to commence trading on the Nasdaq Capital Market during the week of June 7, 2021 under the symbol "SLHG", subject to the Company meeting the applicable bid price requirement for listing during the period beginning on the date of the Company's share consolidation on May 28, 2021 through the initial listing date. Skylight Health will retain its listing on The TSX Venture Exchange under the symbol "SHG". The Company will continue to trade to trade on the OTCQX under the symbol "SGHFF" until trading on the Nasdaq commences.

07:14 EDT Anterix, Nokia partner to offer private LTE across U.S. utility sector - Anterix (ATEX) and Nokia (NOK) announced an agreement designed to accelerate the deployment of 900 MHz private LTE across the U.S. utility sector. The companies will work together to combine Anterix's "beach-front" 900 MHz spectrum with Nokia's industrial-grade private LTE/4.9G wireless infrastructure so that utility companies can deploy private LTE solutions that support advanced communications. Nokia is also a charter member of the Anterix Active Ecosystem Program that brings together technology companies to support Anterix customers deploying and operating private LTE on 900 MHz. The joint solution will include the Nokia Digital Automation Cloud platform and Nokia Modular Private Wireless solution.

07:12 EDT CVS Health announces sweepstakes to encourage vaccinations - CVS Health announced that beginning June 1, eligible customers who received or plan to receive a COVID-19 vaccination through CVS Health may choose to enter the #OneStepCloser sweepstakes for an opportunity to win one of over a thousand fun and exciting prizes through weekly drawings and grand prizes over a six-week period.

07:12 EDT Oncorus announces nomination of synthetic vRNA immunotherapy product candidates - Oncorus announced the nomination of its first Synthetic viral RNA immunotherapy clinical candidates, ONCR-021 and ONCR-788. Oncorus' pioneering intravenous-administered approach involves encapsulating the genomes of RNA viruses known to kill cancer cells in a lipid nanoparticle, creating a Synthetic vRNA immunotherapy. ONCR-021 encodes an optimized strain of Coxsackievirus A21, and ONCR-788 encodes for a modified version of the Seneca Valley Virus. Both CVA21 and SVV have extensive clinical experience and favorable safety profiles when administered IV. Oncorus' novel Synthetic vRNA approach holds the potential for IV-administration and avoids the challenge of neutralizing antibodies seen in previous approaches with IV-administered OVs. Oncorus plans to investigate its novel Synthetic vRNA immunotherapies in multiple histologies including cancers of the lung both as monotherapy and in combination with immune checkpoint inhibitors and other cancer treatments.

07:10 EDT Provention Bio: Nasdaq halts trading of company's stock - Provention Bio announced that Nasdaq has halted trading of the company's common stock. The U.S. FDA Endocrinologic and Metabolic Drugs Advisory Committee is meeting on 5/27 to discuss the Biologics License Application for teplizumab for the delay of clinical type 1 diabetes in at-risk individuals. The Advisory Committee meeting is scheduled to start at 9:00 a.m. ET.

07:09 EDT Broadwind announces completion of at-the-market equity program - Broadwind announced the completion of its previously announced at-the-market equity program. On March 9, 2021, Broadwind announced that it had entered into an equity distribution agreement under which the Company may sell from time to time through Craig-Hallum Capital Group LLC up to $10M of common stock under the Company's effective "shelf" registration statement on Form S-3, including the related prospectus and prospectus supplement. As of May 26, 2021 the Company had sold an aggregate of 1.9 million shares of common stock, resulting in net proceeds of $9.7M, thereby completing the program.

07:07 EDT uniQure says DSMB recommends proceeding with Phase I/II trial of AMT-130 - uniQure announced that the independent Data Safety Monitoring Board overseeing the Phase I/II clinical trial of AMT-130 for the treatment of Huntington's disease has met and reviewed safety data for the fully enrolled first cohort of ten patients. This data set included nine-month safety data from the first two enrolled patients, six-month safety data from the next two enrolled patients, and 30-day safety data on remaining six patients in the trial. The DSMB recommended continued dosing in the study, and uniQure will now begin to enroll patients in the higher-dose cohort of the trial. The Phase I/II study is a double-blind, randomized clinical trial being conducted in the United States. To date, six patients have been treated with AMT-130, and four patients received the imitation surgery.

07:06 EDT Concert Pharmaceuticals initiates THRIVE-AA2 trial - Concert Pharmaceuticals announced it has initiated THRIVE-AA2, the second planned Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata. The company expects to report topline results from THRIVE-AA2 in the second half of 2022. Under current timelines, the company believes that results from two Phase 3 trials could serve as the basis for submitting a new drug application to FDA in early 2023 for CTP-543 for the treatment of moderate to severe alopecia areata in adult patients.

07:05 EDT Dynavax announces pact with Bavarian Nordic for commercialization of HEPLISAV B - Dynavax announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B in Germany with an expected launch in the fourth quarter of 2021. In February 2021, the European Commission granted marketing authorization for HEPLISAV B for the active immunization against hepatitis B virus infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV B is the only U.S. FDA and EC approved hepatitis B vaccine for adults with a two-dose regimen that is completed in one month.

07:04 EDT FDA approves Lantheus' PYLARIFY, an F 18-labeled PSMA - Lantheus Holdings announced that the U.S. Food and Drug Administration has approved PYLARIFY, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography imaging agent to identify suspected metastasis or recurrence of prostate cancer. PYLARIFY is the first and only commercially available approved PSMA PET imaging agent for prostate cancer. The product will be immediately available in parts of the mid-Atlantic and southern regions and availability is expected to rapidly expand over the next six months with broad availability across the U.S. anticipated by year end. "The FDA approval of PYLARIFY is a significant milestone for Lantheus and the prostate cancer community in the United States. We believe PYLARIFY represents a paradigm shift in the identification and management of patients with suspected metastasis or recurrent prostate cancer, providing more accurate and earlier detection of disease than conventional imaging so that doctors, along with patients and their families, can make more informed treatment decisions," said Mary Anne Heino, President and Chief Executive Officer of Lantheus. "I would like to thank the patients who participated in our clinical trials, the study investigators and our employees, whose efforts made this achievement possible."

07:04 EDT Dollar General CEO says Q1 results 'exceeded our expectations' - "We are pleased with our strong start to fiscal 2021, and I want to thank our associates for their unwavering commitment to supporting our customers, communities, and each other," said Todd Vasos, Dollar General's CEO. "As a testament to their efforts, our first-quarter results exceeded our expectations, reflecting strong underlying performance across the business, which we believe was enhanced by the most recent round of government stimulus payment. Given our first-quarter outperformance, we are raising our financial outlook for fiscal 2021." "During the first quarter, we executed more than 800 real estate projects, including new store openings in our pOpshelf and larger footprint Dollar General formats. In addition, we remained focused on serving our customers, while further advancing our key strategic initiatives. Looking ahead, we are excited about our plans and believe we are well-positioned to continue delivering long-term sustainable growth and value for our shareholders."

07:01 EDT Tellurian and Gunvor sign 10-year LNG agreement for 3M tons per annum - Tellurian and Gunvor Singapore announced a liquefied natural gas sales and purchase agreement for 3M tons per annum for a ten year period, indexed to a combination of two indices; the Japan Korea Marker and the Dutch Title Transfer Facility, netted back for transportation charges. The LNG would be delivered free on board from Tellurian's Driftwood LNG, a 27.6 mtpa liquefaction facility proposed near Lake Charles, Louisiana. At current LNG prices, this agreement represents the equivalent of approximately $12B in revenue over the 10-year term of the agreement.

06:59 EDT Vasta Platform acquires Redacao Nota 1000 - Vasta Platform, through its wholly-owned subsidiary Somos Sistemas de Ensino, acquired Nota 1000 Servicos Educacionais. Redacao Nota 1000 provides individual and automated essay review services, through a license of its "software as a service" platform. Founded in 2014, Redacao Nota 1000 has provided services to over 270 schools and 700,000 students, with more than 1.3 million essays reviewed. Redacao Nota 1000 expects to record net revenue of R$4.9M in 2021.Redacao Nota 1000 will also provide significant product enhancement for core brands with the incorporation of Redacao Nota 1000 solutions for reviewing essays within Vasta's K-12 school platform.

06:53 EDT Tempur Sealy to acquire Dreams for $475M, sees accretion - Tempur Sealy announced it has executed an agreement to acquire Dreams, the specialty bed retailer in the United Kingdom, primarily from an affiliate of Sun Capital Partners. The transaction price is approximately $475M, less net debt and any working capital deficit, and the transaction is expected to be accretive to Tempur Sealy's EPS by approximately 20c before synergies in the first year post-acquisition.Dreams has developed a multi-channel sales strategy, with over 200 brick and mortar retail locations, an online channel, as well as manufacturing and delivery assets. Dreams generated sales of approximately $400M and EBITDA of approximately $75M for the year ending December 31, 2020. Dreams is expected to generate annual sales of approximately $450M in the first year post-acquisition. Dreams will be operated as an independent business unit and led by the current management team. It is expected to complement the company's existing UK Tempur operations and its recently-formed Sealy UK joint venture operations. After the transaction closes, Tempur Sealy's annualized worldwide direct-to-consumer business is expected to reach $1B in sales and its international segment will represent over 20% of consolidated sales. The transaction will be financed through a combination of cash on hand and bank borrowings. The company's pro forma leverage is expected to be slightly less than 2 times adjusted EBITDA as defined in the company's credit agreement. The transaction is expected to close in Q3, subject to receipt of regulatory approval from the UK Financial Conduct Authority.

06:50 EDT Medtronic increases quarterly cash dividend to 63c per share - Medtronic announced that the Medtronic board of directors approved an increase in Medtronic's cash dividend for Q1, raising the quarterly amount to 63c per ordinary share. This would translate into an annual amount of $2.52 per ordinary share, a 9% increase from the prior $2.32.

06:49 EDT Burlington Stores reports Q1 gross margin 43.3% vs. 41% in 1Q19 - An increase of 230 basis points.

06:45 EDT Sanofi, GSK initiate Phase 3 clinical efficacy study of COVID vaccine candidate - Sanofi (SNY) and GlaxoSmithKline (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate. The global randomized, double-blind, placebo-controlled Phase 3 study will include more than 35,000 volunteers aged 18 and older from several countries, including sites in the US, Asia, Africa and Latin America. The primary endpoint of the study is the prevention of symptomatic COVID-19 in SARS-CoV-2 naive adults, with secondary endpoints being the prevention of severe COVID-19 disease and prevention of asymptomatic infection. In a two-stage approach, the study will initially investigate the efficacy of a vaccine formulation targeting the original D.614 virus, while a second stage will evaluate a second formulation targeting the B.1.351, or South African, variant. The design of the Phase 3 study, conducted across a broad diversity of geographies, also allows evaluation of the efficacy of the candidate against a variety of circulating variants. "We are encouraged to see first vaccinations starting to take place in such an important, pivotal Phase 3 study, as we believe that our unique technology platform will provide a clinically-relevant vaccine option. We have adapted our vaccine development strategy based on forward-looking considerations as the virus continues to evolve, as well as anticipating what may be needed in a post-pandemic setting," said Thomas Triomphe, Executive Vice President, Global Head of Sanofi Pasteur.

06:39 EDT E2open sees mid-teens FCF per share accretion from BluJay deal in year one - Transaction highlights: Increased scale as the pro forma company expects to deliver annualized pro forma revenue of over $550M and adjusted EBITDA greater than $200M post completion of the combination and the realization of acquisition-related cost synergies. The combined company will deliver pro forma organic revenue growth greater than 10% in fiscal year 2023. E2open expects mid-teens FCF per share accretion on a pro forma basis over the next 12 months. $20M of projected run-rate cost savings, reflecting 5% of combined company costs. Accelerates organic revenue growth and higher net retention post combination due to significant cross-sell opportunities.

06:35 EDT Toronto-Dominion CEO calls Q2 results 'strong' - "TD reported strong results in the second quarter, reflecting the underlying strength of our diversified businesses, improving economic conditions and our prudent approach to managing risk," said Bharat Masrani, Group President and CEO, TD Bank Group. "We continued to invest in our people, capabilities and technology to position our business for growth as economies re-open and consumer and business activity recovers." "While we are encouraged by the progress being made on vaccinations, COVID-19 continues to be a factor in our lives and our focus remains on the safety of our people and on supporting the evolving needs of our customers and clients," added Masrani. "As we look toward the future, we will continue to advance our strategy and contribute to a robust and inclusive recovery, guided by our purpose to enrich the lives of our customers, colleagues and communities."

06:33 EDT E2open to combine with BluJay Solutions in $1.7B deal - E2open Parent Holdings announced that it will acquire BluJay Solutions, a cloud-based, logistics execution platform. Based on the price of E2open's Class A Common Stock at May 25, market close, the stock and cash transaction is valued at approximately $1.7B. Pursuant to the purchase agreement, E2open will acquire BluJay Solutions for an aggregate of 72.4M shares of Class A Common Stock and ~$760M of cash, which includes the repayment of debt, subject to adjustments for certain items enumerated in the purchase agreement. Based on the price of E2open's Class A Common Stock at May 25 market close, the stock and cash transaction is valued at approximately $1.7B. The actual transaction value will change based on fluctuations in the price of E2open's common stock, and is subject to certain adjustments as set forth in the purchase agreement. As a result, current BluJay shareholders will hold approximately 22% pro forma ownership of E2open following the consummation of the transaction. Certain of BluJay's current shareholders, Francisco Partners and Temasek, will have the right to appoint one director each to the E2open board following closing subject to the terms of the agreement. In order to finance the transaction, E2open has secured $300M in a common equity PIPE from institutional investors including Neuberger Berman, The WindAcre Partnership, Eminence Capital and XN, and a $380M fully committed incremental tack-on to its first lien term loan. Pro forma net leverage is expected to be approximately 4.1x fiscal year 2022 EBITDA at closing and approximately 3.5x by the end of fiscal year 2022. The transaction was unanimously approved by E2open's board of directors and is expected to close during the calendar year third quarter of 2021 subject to regulatory approvals, required approval of E2open shareholders and other customary closing conditions.

06:25 EDT Tesla has installed 200,000 Powerwalls around the world - Tesla has installed 200,000 Powerwalls, the company's home battery storage product, around the world, the company said in a tweet on Wednesday. Reference Link

06:06 EDT CytoDyn's Brazilian partner submitting Phase 3 leronlimab authorization - CytoDyn's Brazilian distribution partner, Biomm, plans to submit an authorization request to the Brazilian National Health Surveillance Agency in the next few days to conduct two Phase 3 clinical trials of leronlimab in Brazil for COVID-19. The two Phase 3 trials consist of trials for each severe and critically ill COVID-19 patients. The COVID-19 trials in Brazil are intended to provide ANVISA with the requisite data to consider advancing the availability of leronlimab to thousands of Brazilians infected with COVID-19. These two Phase 3 trials will be conducted in up to 45 clinical sites. The critically ill protocol is for 306 patients while the severe protocol is for 594 patients, and interim analysis for both populations will be conducted when enrollment reaches about 40% of the total number for each trial. The FDA granted CytoDyn Fast Track designation to explore two potential indications using leronlimab to treat HIV and metastatic cancer. CytoDyn is also conducting a Phase 2 clinical trial for NASH to evaluate the effect of leronlimab on liver steatosis and fibrosis.

05:25 EDT Cathay General to acquire 10 HSBC branches in California, sees accretion - Cathay General (CATY) announced that its subsidiary bank, Cathay Bank, has entered into a purchase and assumption agreement with HSBC (HSBC), to purchase 10 HSBC retail branches in California and additional loans and deposits associated with HSBC's West Coast mass retail market consumer banking business and retail business banking business. Under the terms of the purchase and assumption agreement, Cathay Bank will acquire 10 HSBC branches and purchase and assume additional deposit liabilities and assets, including residential mortgage loans, retail business banking loans and personal loans associated with HSBC's West Coast mass retail market consumer banking business and retail business banking business. Cathay Bank is not acquiring or assuming loans or assets associated with HSBC's brokerage business, its private banking and high net worth businesses or its non-retail business banking business. The transaction is expected to be completed during the first quarter of 2022, subject to regulatory approval. As of March 31, the total acquired loans were approximately $0.8B and total deposit were approximately $1B. The financial terms of the agreement were not disclosed. The transaction is expected to be approximately 2% accretive to Cathay General Bancorp's GAAP 2022 earnings per share, on a run-rate basis, excluding any one-time transaction costs and restructuring expenses.

05:18 EDT Gap, Walmart partner to introduce Gap Home collection - Gap (GPS) and Walmart (WMT) announced a strategic partnership to introduce Gap Home, a new brand of home essentials available exclusively at Walmart. Gap Home embodies the brand's optimistic, modern American style that bridges the gaps between individuals, generations and cultures. The launch collection features materials like denim and chambray. The Gap Home collection includes items made with organic cotton and recycled materials.

05:09 EDT Scientific Games, Evolution announce Lightning Roulette game agreement - Evolution has announced that it has signed an exclusive agreement with Scientific Games to make Evolution's live online Lightning Roulette game available as a physical game in land-based casinos worldwide. The deal will see the Evolution Lightning Roulette live wheel, with its game setting with integrated random RNG multipliers, made available from Scientific Games to land-based casinos worldwide. It will be the first Evolution game, other than the company's Dual Play Roulette and Baccarat games which are tables that are streamed from land-based casinos tables, to make the transition from live to land-based.